FibroGen (NASDAQ:FGEN) announced its earnings results on Monday. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.59) by $0.02, Briefing.com reports. The firm had revenue of $33.17 million during the quarter, compared to analyst estimates of $31.61 million. FibroGen had a net margin of 13.90% and a return on equity of 9.01%. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.50) EPS.
Shares of FibroGen stock traded down $0.76 during trading hours on Tuesday, reaching $34.64. 26,941 shares of the company’s stock were exchanged, compared to its average volume of 810,108. The company has a 50 day moving average of $38.61 and a two-hundred day moving average of $41.88. FibroGen has a fifty-two week low of $33.51 and a fifty-two week high of $61.23. The company has a current ratio of 9.73, a quick ratio of 9.71 and a debt-to-equity ratio of 0.07. The stock has a market cap of $3.62 billion, a P/E ratio of -33.86 and a beta of 1.84.
A number of equities analysts recently weighed in on FGEN shares. Mizuho reaffirmed a “positive” rating and issued a $72.00 target price (up from $65.00) on shares of FibroGen in a research note on Monday. ValuEngine raised shares of FibroGen from a “hold” rating to a “buy” rating in a research note on Friday. TheStreet raised shares of FibroGen from a “d+” rating to a “c” rating in a research note on Tuesday, August 13th. BidaskClub raised shares of FibroGen from a “sell” rating to a “hold” rating in a research note on Thursday, October 17th. Finally, Zacks Investment Research raised shares of FibroGen from a “hold” rating to a “buy” rating and set a $51.00 target price for the company in a research note on Tuesday, August 13th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. FibroGen currently has a consensus rating of “Buy” and an average price target of $58.33.
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Featured Article: What are retained earnings?
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.